Citius Pharmaceuticals, Inc. CTXR 深 滬
已收盤 08-01 16:00:00 美东时间
1.29
-0.080
-5.84%
華盛通- 最 高1.333
- 今 開1.31
- 成交量 31.66万股
- 最 低 1.26
- 昨 收 1.37
- 總市值 1962.13万
- 52周最高 19.995
- 市盈率 靜 --
- 換手率 2.08%
- 52周最低 0.65
- 委 比 91.53%
- 總股本 1521.03万
- 歷史最高 137.25
- 量 比 0.88
- 振 幅 5.33%
- 歷史最低 0.65
- 每 手 1
- 風險率 5.64%
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Citius Oncology Announces Pricing of $9.0 Million Public Offering
CRANFORD, N.J., July 16, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology" or the "Company") (Nasdaq: CTOR), a majority-owned subsidiary of Citius Pharmaceuticals, Inc. (Nasdaq: ...
07-16 21:15
Cencora distribution deal boosts Citius shares
Citius Pharmaceuticals (NASDAQ:CTXR) traded higher in the premarket on Tuesday after the company announced that its majority-owned subsidiary, Citius Oncology (NASDAQ:CTOR), reached a distribution ser...
07-15 20:56
Citius Oncology Partners With Cencora To Boost Commercial Launch And Distribution Of FDA-Approved Immunotherapy LYMPHIR
Agreement with global pharmaceutical solutions provider enhances commercial infrastructure and reinforces launch readiness for FDA-approved immunotherapy LYMPHIR™CRANFORD, N.J., July 15, 2025 /PRNewswire/ --
07-15 20:35
Citius Pharmaceuticals regains Nasdaq compliance
Citius Pharmaceuticals (NASDAQ:CTXR) announced on Tuesday it received a Nasdaq notification, indicating that the company regained compliance with Nasdaq's minimum bid price requirement rule of $1.00 p...
07-08 20:48
Citius Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Requirement
CRANFORD, N.J. , July 8, 2025 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR) today announced that it has received formal notification from Th...
07-08 20:34
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
美股大行评级 | 巨大分歧！Circle获多家大行首予评级目标价在80~250之间；Stifel上调甲骨文评级至"买入"，目标价升至250美元
07-01 09:24
D. Boral Capital Maintains Buy on Citius Pharmaceuticals, Maintains $6 Price Target
D. Boral Capital analyst Jason Kolbert maintains Citius Pharmaceuticals (NASDAQ:CTXR) with a Buy and maintains $6 price target.
06-30 19:24
Citius Oncology Anticipates Commercial Launch of LYMPHIR™ in 2025
CRANFORD, N.J., June 17, 2025 /PRNewswire/ -- Citius Oncology, Inc. ("Citius Oncology") (Nasdaq: CTOR), the oncology-focused subsidiary of Citius Pharmaceuticals, Inc. ("Citius Pharma") (Nas...
06-17 20:08
Citius Pharmaceuticals Closes $6M Securities Offering
An update from Citius Pharmaceuticals ( ($CTXR) ) is now available. On June 9, ...
06-12 21:17
美股大行评级 | 潜在涨幅434.95%！VNRX获Jones Trading首予"买入"评级，目标价3美元
<span> <meta content="no-referrer" name="referrer"></span><p>https://static-hk.hstong.com/public/forum-v2/status/icon/50267976/originalpic/1139478829918380033.png</p><span style="color:#999999;">编者按：每日追踪华尔街最新评级与目标价，挖掘潜力股投资机会。</span><blockquote> <p><span style="color:#fa1432;"><strong>今日重点评级关注</strong></span></p></blockquote><p>• Guggenheim：维持Metsera(MTSR)"买入"评级，目标价从56美元升至62美元</p> <p>• 摩根大通：维持Avidity Biosciences(RNA)"超配"评级，目标价从57美元升至59美元</
06-11 09:43
